UK courts antibiotic developers with 'subscription-style' incentive to combat superbug scourge
As antibiotic developers languish, and superbugs flourish, the United Kingdom is taking a key step to invigorate antimicrobial development by wooing manufacturers with the incentive of a ‘subscription’ style payment: the drugs will be paid for, even if they’re just stored in reserves.
It is no secret that the industry players contributing to the arsenal of antimicrobials are fast dwindling. Drugmakers are enticed by greener pastures, compared to the long, arduous and expensive path to antibiotic approval that offers little financial gain as treatments must be priced cheaply, and often lose potency over time as microbes grow resistant to them. Consequently, there has been no new class of antibiotics approved since the 1980s — and today, roughly 700,000 deaths annually are attributed to drug resistant bacteria, according to the WHO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.